Title:
K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345
Protocol Number:
J0625
Phase:
Pilot
Physician:
B Douglas Smith
Purpose:
1.Determine whether a series of four K562/GM-CSF vaccinations (+/- imiquimod cream) can serve as an immunologic ?booster? and result in molecular remissions in subjects considered non-responders to imatinib mesylate + a primary series of K562/GM-CSF vaccines OR return subjects who have recurrent measurable disease after an initial complete molecular remission to imatinib mesylate + and a series of K562/GM-CSF vaccines to molecular negativity.
Eligibility:
Patients with AML who completed the entire protocol of J0345 and still ahve evidence of disease.
Treatment:
4 vaccines seperated by 3 weeks. Each vaccine will be given over 10 seperate injectiopn sites to the lower legs and upper arm.
Population:
Adult
Last Update
05/22/2013 04:02 AM
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts